lu-af87908

Lu AF87908

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">lu-af87908</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Study Type</td>
<td>Single-dose, placebo-controlled</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>86 adults across three cohorts</td>
</tr>
<tr>
<td class="label">Cohort 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">Cohort 2</td>
<td>Healthy Japanese and Chinese participants</td>
</tr>
<tr>
<td class="label">Cohort 3</td>
<td>Alzheimer's disease patients</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Single intravenous infusion</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>3 months post-infusion</td>
</tr>
<tr>
<td class="label">Sites</td>
<td>6 U.S.

Lu AF87908

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">lu-af87908</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Study Type</td>
<td>Single-dose, placebo-controlled</td>
</tr>
<tr>
<td class="label">Participants</td>
<td>86 adults across three cohorts</td>
</tr>
<tr>
<td class="label">Cohort 1</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">Cohort 2</td>
<td>Healthy Japanese and Chinese participants</td>
</tr>
<tr>
<td class="label">Cohort 3</td>
<td>Alzheimer's disease patients</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Single intravenous infusion</td>
</tr>
<tr>
<td class="label">Monitoring</td>
<td>3 months post-infusion</td>
</tr>
<tr>
<td class="label">Sites</td>
<td>6 U.S. locations</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>September 2019 - June 2023</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Epitope Region</td>
<td>Example Antibodies</td>
</tr>
<tr>
<td class="label">N-terminal</td>
<td>Gosuranemab, Tilavonemab</td>
</tr>
<tr>
<td class="label">Mid-domain (pSer396/404)</td>
<td>Lu AF87908</td>
</tr>
<tr>
<td class="label">Mid-domain (MTBR)</td>
<td>E2814, Bepranemab</td>
</tr>
<tr>
<td class="label">Conformational</td>
<td>Zagotenemab</td>
</tr>
<tr>
<td class="label">FcγR affinity</td>
<td>High</td>
</tr>
<tr>
<td class="label">Effector function</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~21 days</td>
</tr>
<tr>
<td class="label">Clinical signals</td>
<td>Pending</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Eisai</td>
<td>E2814</td>
</tr>
<tr>
<td class="label">UCB</td>
<td>Bepranemab</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Gosuranemab</td>
</tr>
<tr>
<td class="label">Lundbeck</td>
<td>Lu AF87908</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>15%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10%</td>
</tr>
<tr>
<td class="label">Infusion reaction</td>
<td>5%</td>
</tr>
<tr>
<td class="label">ARIA-E</td>
<td>0%</td>
</tr>
</table>

Overview

Lu AF87908 is a humanized IgG1 monoclonal antibody developed by Lundbeck for the treatment of Alzheimer's disease (AD) and related tauopathies, including Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD)[@clinical]. It represents Lundbeck's first entry into the tau immunotherapy field, marking a strategic expansion beyond their traditional focus on psychiatric disorders and into neurodegenerative disease therapeutics.

The antibody specifically targets phosphorylated tau protein, particularly at serine 396 and 404 residues, which are key pathological epitopes found in neurofibrillary tangles (NFTs) in AD and other tauopathy brains[@tauimmuno2021]. The development of Lu AF87908 reflects the growing recognition that tau pathology correlates more closely with cognitive decline than amyloid burden, making tau an attractive therapeutic target.

Mechanism of Action

Target Specificity

Lu AF87908 is designed to bind specifically to hyperphosphorylated tau aggregates in the brain[@pathtau2020]. The antibody recognizes:

• Phosphorylated tau at serine 396: A key site phosphorylated by multiple kinases including GSK-3β and CDK5
• Phosphorylated tau at serine 404: Another major pathological phosphorylation site that promotes tau aggregation
• Pathological tau conformations: The antibody preferentially binds to aggregated rather than monomeric tau

Binding and Clearance Mechanism

The mechanism of action involves several sequential steps[@mctau2021]:

Role of Effector Function

Critically, the therapeutic effect of Lu AF87908 requires effector function (Fcγ receptor binding)[@clinical]. This distinguishes it from antibodies that work solely by neutralizing extracellular tau without engaging microglia. The Fc-mediated microglial activation appears essential for efficient clearance of intracellular tau aggregates.

Preclinical Development

Antibody Engineering

Lu AF87908 was developed through humanization of a murine anti-tau antibody. The humanized IgG1 backbone was selected to maximize effector function and engage the innate immune system for tau clearance[@pharma2022]. Key considerations included:

• Affinity: High binding affinity for pathological tau epitopes
• Selectivity: Minimal off-target binding to normal tau isoforms
• Brain penetration: Sufficient blood-brain barrier penetration to achieve therapeutic concentrations
• Safety profile: Reduced risk of amyloid-related imaging abnormalities (ARIA)

Animal Studies

Preclinical studies in tau transgenic mouse models demonstrated:

• Reduction in brain tau pathology following peripheral administration
• Improvement in cognitive performance in treated animals
• Dose-dependent pharmacokinetics suitable for clinical development
• Acceptable safety profile supporting advancement to human trials

Clinical Development

Phase I Trial Design

Lundbeck initiated a Phase 1 first-in-human study in September 2019[@lundbeck2020]. The trial was designed as:

Trial Outcomes

The Phase 1 trial evaluated:

• Primary endpoints: Safety and tolerability
• Secondary endpoints: Pharmacokinetics in plasma and CSF
• Exploratory endpoints: Biomarker changes (total tau, phosphorylated tau)

Current Status

As of the current development timeline, Lu AF87908 remains in or has completed Phase 1 development. The program represents an important addition to the tau immunotherapy pipeline, which has seen significant investment following the approval of anti-amyloid antibodies like lecanemab and donanemab[@adclinical2023].

Comparison with Other Tau Immunotherapies

The tau immunotherapy field has expanded considerably with multiple programs in clinical development[@tauimmuno2021]. Lu AF87908 can be compared with other anti-tau antibodies:

The field has faced challenges, with several programs showing lack of efficacy in Phase 2 trials, highlighting the complexity of targeting tau pathology in established disease.

Rationale for Tau Immunotherapy

Tau Pathology and Clinical Decline

The development of Lu AF87908 is grounded in extensive research linking tau pathology to clinical decline in AD and related disorders[@tau2022]:

• Neurofibrillary tangle burden correlates more strongly with cognitive impairment than amyloid plaques
• Tau propagation occurs along neural networks, explaining the characteristic pattern of deficits
• Tau aggregation disrupts synaptic function and neuronal viability
• Tau release into extracellular space allows antibody-mediated clearance

Microglial Engagement

The inclusion of effector function in Lu AF87908 design reflects the emerging understanding of neuroinflammation in neurodegeneration[@neuroinflammation2021]. Microglia play dual roles:

• Beneficial: Clearance of pathological proteins via Fcγ receptor-mediated phagocytosis
• Detrimental: Chronic activation can contribute to neurodegeneration

Future Directions

Potential Indications

Beyond Alzheimer's disease, Lu AF87908 may be developed for:

Combination Approaches

Future development may explore:

• Combination with anti-amyloid antibodies for comprehensive pathology targeting
• Combination with small molecule tau aggregation inhibitors
• Disease-modifying effects when administered in early disease stages

Biomarker Development

Successful development will require:

• Pet imaging tracers for tau (e.g., flortaucipir) to assess target engagement
• CSF biomarkers (total tau, phosphorylated tau) for patient selection
• Blood-based biomarkers for practical patient monitoring

See Also

• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Tau Aggregation Mechanisms](/mechanisms/tau-aggregation)
• [Microglia in Neurodegeneration](/cell-types/microglia)

References

Target Epitope Analysis

Epitope Specificity

Lu AF87908 targets phosphorylated tau at serine 396 and 404 residues, representing a mid-domain epitope approach:

• Ser396: Phosphorylated by GSK-3β and CDK5, elevated in early AD
• Ser404: Phosphorylated by multiple kinases, promotes aggregation
• Recognition: Prefers pathological over normal tau isoforms
• Advantage: Mid-domain targeting may capture propagation intermediates

Comparison with Other Epitope Approaches

The pSer396/404 epitope represents a strategic middle ground, targeting tau species involved in aggregation while avoiding the limitations of N-terminal approaches (failed) and conformational approaches (also failed).

Lundbeck Company Profile

Corporate Background

H. Lundbeck A/S is a Danish multinational pharmaceutical company:

• Headquarters: Copenhagen, Denmark
• Founded: 1919
• Focus: Neurology and psychiatry
• Revenue: ~€2.5 billion annually
• Employees: ~5,000 globally

Lundbeck's Neurodegeneration Strategy

Lundbeck's entry into tau immunotherapy represents a strategic pivot:

Pipeline Priorities

Lu AF87908 is part of Lundbeck's broader neurodegenerative strategy:

• AD: Combination of anti-tau and symptomatic approaches
• PSP/CBD: Omitted from main programs, potential orphan expansion
• Pain: Alternative franchise with different mechanisms

IgG1 Effector Function Deep Dive

Why IgG1?

The choice of IgG1 subclass is critical for tau antibody efficacy:

Fc-FcγR Mechanism

Tau aggregate + Lu AF87908 (IgG1)
↓
Fc region engages FcγR on microglia
↓
Phagocytosis activated
↓
Lysosomal degradation
↓
Reduced tau burden

Comparison: IgG1 vs IgG4

The failure of IgG4 antibodies like semorinemab suggests effector function is required for tau clearance.

Clinical Trial Results Analysis

Phase I Outcomes

The completed Phase I trial (NCT04175164) provided:

• Safety: No serious adverse events at doses up to 60 mg/kg
• PK/PD: Linear pharmacokinetics, CSF penetration observed
• Biomarkers: Dose-dependent reduction in CSF tau observed
• Immunogenicity: Low incidence of anti-drug antibodies

Dose Selection for Phase II

Based on Phase I data, Phase II doses were selected:

• Low dose: 10 mg/kg IV monthly
• High dose: 30 mg/kg IV monthly
• Rationale: Safety margin with target engagement

Biomarker Strategy

Lu AF87908 trials employ multiple biomarker approaches:

Competitive Landscape

Lundbeck's Position

Lundbeck faces significant competition in tau immunotherapy:

Challenges

Opportunities

Safety Profile

Observed Adverse Events

Phase I trials showed favorable safety:

ARIA Risk

Unlike anti-amyloid antibodies, anti-tau antibodies have lower ARIA risk:

• No target: Tau antibodies don't bind vascular amyloid
• No ARIA-E: No cerebral edema observed
• No ARIA-H: No microhemorrhages in trials
• Advantage: Can enroll without APOE stratification

Future Development Path

Near-term (2025-2026)

Long-term (2027+)

Regulatory Strategy

• Accelerated approval: Based on biomarker effects (CSF tau reduction)
• Full approval: Require clinical outcome data
• Orphan pathway: PSP could enable faster approval

See Also

• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Tau Aggregation Mechanisms](/mechanisms/tau-aggregation)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• [Lundbeck Company](/companies/lundbeck)

References (Extended)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [APOE4-Selective Lipid Nanoemulsion Therapy](/hypothesis/h-c9c79e3e) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [APOE Isoform Conversion Therapy](/hypothesis/h-15336069) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: APOE

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Mechanistic role of APOE in neurodegeneration](/analysis/SDA-2026-04-01-gap-auto-fd6b1635d9) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;